[Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Imatinib mesylate, a selective Ab1 tyrosine kinase inhibitor (TKI), is the first choice of therapy for CML and has been dramatically improving the prognosis of patients with chronic phase CML. Now that second generation TKIs including nilotinib and dasatinib is available for imatinib-intolerant or resistant patients, the therapeutic algorithm should be revised and updated. As for AML, a number of clinical trials using TKIs targeting FLT3, whose internal tandem duplication is one of the poor prognostic factors in AML, are in progress and FLT3 inhibitors in combination with chemotherapeutic agents will be promising for relapsed and refractory patients in the near future.
Tojo
Arinobu
A
Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D015195:Drug Design; D006801:Humans; D000068877:Imatinib Mesylate; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; C498826:nilotinib; D000069439:Dasatinib